Want to see PMN full AI Analyst Report?

ProMIS Neurosciences (PMN) Price & Analysis

300 Followers

PMN Stock Chart & Stats

$12.20

$0.16(1.28%)

At close: Jul 27 4:00 PM EDT

$12.20

$0.16(1.28%)

Day’s Range― - ―

52-Week Range$6.27 - $27.40

Previous CloseN/A

Volume4.70K

Average Volume (3M)75.89K

Market Cap

$133.80M

Enterprise Value$19.05

Total Cash (Recent Filing)$63.85M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Aug 17, 2026

EPS Estimate

-1.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-23.59

Shares Outstanding8,967,693

10 Day Avg. Volume133,844

30 Day Avg. Volume75,892

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-9.53K

Price to Sales (P/S)0.00

P/FCF Ratio-426.74

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$35.96

Price Target Upside194.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-5.28

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Progress: PMN310 Interim Safety & BiomarkersBlinded interim data showing favorable safety across genotypes, no ARIA‑E, and early biomarker reductions materially de‑risks PMN310's clinical profile. Over 2–6 months this strengthens the program's chance to reach unblinded efficacy readouts and attracts partners, underwriting longer‑term development and partnership optionality.

Low Leverage And Meaningful Equity BaseA no‑debt balance sheet with a meaningful equity cushion lowers financial risk and preserves flexibility to fund near‑term R&D without interest burden. Structurally, this supports continuity of clinical programs and gives the company negotiating leverage with potential collaborators over the medium term.

Oligomer-selective Antibody PlatformThe oligomer‑selective approach targets pathogenic conformations rather than plaques, addressing a key limitation of existing therapies (ARIA risk). This differentiated mechanism is a durable competitive advantage, supporting pipeline breadth, potential label differentiation, and longer‑term licensing or partnership value across neurodegenerative indications.

Bears Say

Pre-revenue With Heavy Cash BurnAs a pre‑revenue biotech, PMN runs sizable recurring losses and negative operating/free cash flow, necessitating external capital. Over months this cash burn constrains runway, raises execution risk for trials, and increases the likelihood of dilutive financings if non‑dilutive partnerships or milestone inflows do not materialize.

Inconsistent Equity Position HistoricallyPeriods of negative equity indicate balance‑sheet volatility and past capital strain. This structural instability can weaken investor and partner confidence, elevate the perceived cost of capital, and complicate long‑term planning and contract negotiations for non‑dilutive funding or strategic alliances.

Reliance On Financings And Dilution RiskThe business model depends on equity financings and incentive share reserves to fund operations and retain talent. Structurally, recurring reliance on equity and expanded compensation capacity implies persistent dilution risk, which can erode shareholder value over time absent milestone success or significant non‑dilutive partnership revenues.

ProMIS Neurosciences News

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy...

4d ago

PMN

ProMIS Neurosciences price target raised to $33 from $20 at Chardan

Chardan analyst Keay Nakae raised the firm’s price target on ProMIS Neurosciences (PMN) to $33 from $20 and...

5d ago

PMN

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy...

5d ago

PMN

ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial

ProMIS Neurosciences (PMN) announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial...

5d ago

PMN

ProMIS Neurosciences initiated with a Buy at Chardan

Chardan analyst Keay Nakae initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $20 price target...

6d ago

PMN

ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310

ProMIS Neurosciences (PMN) announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer’s drug candidate,...

19d ago

PMN

ProMIS Neurosciences initiated with a Buy at Roth Capital

Roth Capital initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $19 price target The firm’s...

25d ago

PMN

ProMIS Neurosciences initiated with a Buy at Roth Capital

Roth Capital initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $19 price target The firm...

25d ago

PMN

PMN310’s Clean Safety and Promising Biomarkers Drive Buy Rating; $35 Price Target Reiterated

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on ProMIS Neurosciences, with...

3d ago

PMN

ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data

An announcement from ProMIS Neurosciences ( ($PMN) ) is now available. On July 28, 2026, ProMIS Neurosciences reported...

5d ago

PMN

Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on PMN stock, giving a Buy rating on...

18d ago

PMN

ProMIS Neurosciences initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of ProMIS Neurosciences (PMN) with an Overweight rating and no price...

1M ago

PMN

Analyst Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target on Differentiated Alzheimer’s Candidate PMN310

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ProMIS Neurosciences and keeping the price target...

1M ago

PMN

Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile

ProMIS Neurosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

2M ago

PMN

PMN FAQ

What was ProMIS Neurosciences Inc.’s price range in the past 12 months?

ProMIS Neurosciences Inc. lowest stock price was $6.27 and its highest was $27.40 in the past 12 months.

What is ProMIS Neurosciences Inc.’s market cap?

ProMIS Neurosciences Inc.’s market cap is $133.80M.

When is ProMIS Neurosciences Inc.’s upcoming earnings report date?

ProMIS Neurosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.

How were ProMIS Neurosciences Inc.’s earnings last quarter?

ProMIS Neurosciences Inc. released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.

Is ProMIS Neurosciences Inc. overvalued?

According to Wall Street analysts ProMIS Neurosciences Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProMIS Neurosciences Inc. pay dividends?

ProMIS Neurosciences Inc. does not currently pay dividends.

What is ProMIS Neurosciences Inc.’s EPS estimate?

ProMIS Neurosciences Inc.’s EPS estimate is -1.38.

How many shares outstanding does ProMIS Neurosciences Inc. have?

ProMIS Neurosciences Inc. has 8,967,693 shares outstanding.

What happened to ProMIS Neurosciences Inc.’s price movement after its last earnings report?

ProMIS Neurosciences Inc. reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.

Which hedge fund is a major shareholder of ProMIS Neurosciences Inc.?

Currently, no hedge funds are holding shares in PMN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ProMIS Neurosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

393.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

ProMIS Neurosciences (PMN) Earnings & Revenues

Historic Earnings Reports

PMN Stock 12 Month Forecast

Average Price Target

$35.96

▲(194.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","70":"$70","21.25":"$21.3","37.5":"$37.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$69.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.964285714285715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,21.25,37.5,53.75,70],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.45,17.723076923076924,21.996153846153845,26.269230769230766,30.54230769230769,34.815384615384616,39.08846153846154,43.36153846153846,47.63461538461539,51.9076923076923,56.18076923076923,60.45384615384616,64.72692307692307,{"y":69,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.45,15.181868131868132,16.91373626373626,18.645604395604394,20.377472527472527,22.10934065934066,23.841208791208793,25.573076923076922,27.304945054945055,29.036813186813188,30.76868131868132,32.50054945054945,34.23241758241758,{"y":35.964285714285715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.45,13.799999999999999,14.149999999999999,14.5,14.85,15.2,15.549999999999999,15.899999999999999,16.25,16.6,16.95,17.3,17.65,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.218,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.162,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.497,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.377,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.825,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.41,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >